Company intelligence / Profile preview
NoNO Inc.
Toronto, Ontario, Canadanonoinc.ca ↗
- Ownership
- Private
- Employees
- ~96
- Development stage
- Other
01
Overview
NoNO Inc. has advanced its lead candidate, the peptide drug nerinetide, into a global Phase 3 trial ("ESCAPE-NEXT") for acute ischemic stroke. Nerinetide aims to reduce disability and improve outcomes by protecting neurons during and after a stroke event. Previous studies have shown promise for this approach in reducing damage from strokes where rapid intervention can be achieved.
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Peptides (notably nerinetide)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on NoNO Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NoNO Inc..